tirzepatide for osa FDA Approves (Zepbound) as the First Medication Obstructive Sleep Apnea Tirzepatide Demonstrates Reduction in Sleep

JAMA (2022) 327(6):53445

If Congress extends the IRA negotiation framework to commercial insurance prices, the calculus changes completely

Support Monthly visits and progress check-ins to monitor results and adjust your plan as needed

Even more remarkable, a post-hoc analysis revealed that 14.1% of patients on the 9 mg dose and 12% on the 12 mg dose became completely free of knee pain at 68 weeks, compared to just 4.2% taking placebo

Our programs integrate medication with nutritional counseling, lifestyle guidance, and ongoing monitoring

Personalized Treatment Plan Our providers design a dosing schedule and monitoring plan tailored to your needs